SW
FNCH

SVB Wealth’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

SVB Wealth’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,435
Closed -$99.5K – 1025
2023
Q1 		$99.5K Hold
8,435
– – ﹤0.01% 939
2022
Q4 		$121K Hold
8,435
– – ﹤0.01% 956
2022
Q3 		$423K Buy
+8,435
New +$587K 0.01% 568

Other funds holding FNCH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

SVB Wealth's FNCH Position: Q2 2023 in Review

SVB Wealth sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 8,435 shares — an estimated $99.5K sold.

SVB Wealth first reported a position in FNCH in Q3 2022 and held it in 3 quarters. The position peaked at $423K in Q3 2022. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

  • SVB Wealth reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • SVB Wealth sold 8,435 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $99.5K.
  • SVB Wealth first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • SVB Wealth's Finch Therapeutics Group, Inc. Common Stock position peaked at $423K in Q3 2022.
  • 17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on SVB Wealth's 13F filing for Q2 2023, filed 24 Jul 2023.